Invitation for subscription of shares prior to planned listing on AktieTorget

Transcription

1 SORTING CELLS WITH SOUND Invitation for subscription of shares prior to planned listing on AktieTorget Torsten Freltoft, CEO Thomas Laurell, Founder Investor Presentation November

2 Top killers: SEPSIS (blood poisoning) 250,000+ SEPSIS casualties per year in USA alone - and rapidly increasing! 8% p.a. 1

3 Top killers: CANCER 2.5% p.a. 12,000 cancer casualties in Sweden per year - Almost 500,000 in USA 2

4 What to do? Can Sepsis and Cancer be cured? YES they can! If only diagnosed fast or early enough 3

5 Diagnosis today Sepsis Blood sample Blood culturing to multiply bacteria - Can take days! Mass Spec. or DNA analysis to identify type Cancer CT scanning Biopsy if tumor is found! Manual or semi-automated microscopy inspection DNA analysis 4

6 Diagnostic challenge Sepsis and cancer biomarkers present in a simple blood sample BUT no effective separation methods exist for generating enough sample for testing The solution is ACOUSTIC SEPARATION or ACOUSTIC TRAPPING Bacteria Circulating Tumor Cells (CTC) 5

7 Outlets Glass lid (anodic bonding) Inlet Acoustophoretic cell manipulation - a platform technology - Why acoustophoresis and cell handling? Generic technology Harmless to cells Rapid & high throughput Continuous flow Concentration Switching Separation Washing 375 µm 120 MSEK invested in research since researchers currently involved

8 Acoustophoretic isolation of tumor cells CTC - A liquid biopsy to characterize an individual patient s tumor Guide treatment selection based on cancer type Rapid indicator of treatment response Support new drug development and drug approvals 5 um 7 um

9 Acoustic trapping of cells & microparticles Acoustic enrichment of bacteria & nanoparticles Can you trap bacteria and nano-particles? Acoustic seed trapping enables bacteria enrichment Piezotransducer 10 minute time lapse video showing seed particle (10 um) enrichment of fluorescent E. coli Low concentration High concentration Bacteria enrichment in blood Rapid diagnostics - Sepsis Food QC Enrichment of extra cellular vesicles Holy grail for disease biomarkers Cancer Cardiovascular disease Parkinson & Alzheimer disease.

10 Acoustophoretic blood plasma Separation of blood plasma Centrifuge Separation of blood plasma Acoustophoresis Centrifugation - most common diagnostic sample preparation All clincial blood samples are centrifuged Millions of blood plasma centrifugations every day Diagnostic stand alone instruments incorporate a centrifuge Small footprint vs. centrifuge Handles small sample volumes Easy & direct integration with diagnostic instruments OEM module in development

11 Market for specific applications Very large >$200M Blood washing Plasma isolation Circulating Tumor Cells Medium >$20M Microfluidics tools 3D tissue culture Thrombocyte depletion apheresis Sample cleanup service Replace red cell lysis Platelet removal from lymphocytes Particle trapping system Focusing for image cytometry Decomplexing proteomic samples Acoustic cell sorting Cell/particle concentration Biomarker discovery Multistep sample prep for CBA Large >$50M Particle washing Leukoreduction Cleanup of nuclei Bacteria concentration Extracellular vesicle concentration Cell sample processing for cytometry Low <$20M Switching for slow cell sorting Particle focusing for flow cytometry Continuous cell suspension for sorters Bacteriophage selection Acoustic parameters for cytometry Källa: D. Recktenwald, Options for Commercializing AcouSort s Technology,

12 Initial Products AcouTrap Particle trapping system Enabling bacteria & micro vesicle research Commercialization in progress Four systems sold! AcouWash Cell washing station Cell washing station Demonstrator completed Final product maturization in progress Blood plasma separation OEM module Basic feasibility demonstrated Commercial partner in place and advanced feasibility studies completed Development project planned Development so far funded by cash flow from feasibility studies - No external investments made!

13 Commercialization Strategy Strategy Develop and commercialize OEM volume products Alliances with global life science system providers Provide direction and partly finance development for their dedicated applications Sale of generic research tools for acoustic separation and trapping Researchers can practice acoustic separation methods generate early revenues develop strategic collaborations 12

14 Commercialisation Goals Blood plasma OEM module Working with three global partners First product launch 2018 Research instruments AcouTrap (launched) 2017: 10 system sales 2018: 20 system sales AcouWash (launch 2017) 2017: 6 system sales 2018: 10 system sales Financials 2018: Break even 13 A c o u T r a p A c o u W a s h

15 The management team Operational team Torsten Freltoft, PhD CEO Med-tech professional Martin Linde Chairman of Board Business executive Board of directors Pelle Ohlsson, PhD Project Manager, Acoustofluidics expert Thomas Laurell Founder Professor at LU/BME Mikael Evander, PhD Product Manager Cell trapping expert Stefan Scheding MD, PhD Assoc Professor, LU Per Augustsson, PhD IP Manager Acoustofluidics expert Annelie Sylvén Troedsson Lawyer

16 Ownership structure Shareholder Ownership Lock-up agreement Thomas Laurell 19,5 % 12 months Stefan Scheding 15,3 % 12 months Freltec ApS / Torsten Freltoft 15,0 % 12 months LU Holding 14,5 % 12 months Hans Lilja 11,5 % Johan Nilsson 7,4 % Staffansgården i Trää AB 5,0 % 12 months Other Shareholders (5) 11,9 % As of 1 November ,0% 15

17 New emission & listing Subscription offer in summary Subscription period 22 Nov 6 Dec 2016 Price SEK 5.50 per share Maximum capital increase SEK 11M Valuation (pre-money) SEK 30.3M Pre-subscription secured SEK 4.5M (41%) Listing at AktieTorget 9 Jan 2017 (estimated) SORTING CELLS WITH SOUND 16